Core Viewpoint - MicroPort CardioFlow Medtech Corporation-B (02160) announced that all conditions for the share consolidation have been met as of February 24, 2026, and the share consolidation will take effect from that date [1] Group 1 - The share consolidation is a significant corporate action that may impact the company's stock structure and investor perception [1]

Group 1 - The core point of the article is that MicroPort CardioFlow Medtech Corporation (微创心通-B, 02160) has announced that all conditions for the share consolidation have been met as of February 24, 2026, and the share consolidation will take effect from that date [1]

Core Viewpoint - Meikang Bio has recently announced the acquisition of medical device registration certificates for its hepatitis B virus diagnostic products from the National Medical Products Administration and the Jiangxi Provincial Drug Administration [2] Group 1: Company Developments - Meikang Bio and its subsidiary Jiangxi Meikang Shengde Biotechnology Co., Ltd. have obtained the "Medical Device Registration Certificate" for the hepatitis B virus surface antigen test kit and surface antibody test kit, both utilizing chemiluminescent microparticle immunoassay [2] - The registered products include the dry chemical analyzer, indicating an expansion in the company's diagnostic capabilities [2]

Core Viewpoint - The company Fuhua Jia announced the completion of clinical trial registration for its product "Recombinant Type III Humanized Collagen Freeze-Dried Fiber," allowing it to proceed with clinical trials and submit registration materials [2] Group 1: Clinical Trial Progress - The product has passed the ethical review by the Ethics Committee of the Plastic Surgery Hospital of the Chinese Academy of Medical Sciences [2] - The company has completed the clinical trial and obtained the clinical trial summary report [2] - The product is now eligible for the submission of registration application materials [2]

Group 1 - The Goldman Sachs Group, Inc. increased its stake in Aikang Medical (01789) by purchasing 1.42 million shares at a price of HKD 6.26 per share, totaling HKD 8.8892 million [1] - Following the purchase, Goldman Sachs' total shareholding in Aikang Medical is approximately 57.6054 million shares, representing a holding percentage of 5.13% [1]

Group 1 - The core point of the article is that Mingde Biological (002932) reported a total of 24,007 shareholders as of January 31, 2026 [1]

Core Viewpoint - The recent notice from Hubei Province addresses the issue of "abnormally low bidding" in government procurement, particularly targeting bids as low as "1 yuan" or "0.01 yuan" [1][19]. Group 1: Government Procurement Issues - The focus on abnormally low bids is not new, with previous regulations implemented in regions like Jiangxi, Guangxi, and Jiangsu, emphasizing scrutiny on bids below 50% of the average price or 45% of the maximum limit [2][10]. - A notable case involved a hospital with a budget of 3 million yuan for medical equipment, which was awarded to a bid of only 1,000 yuan, leading to increased costs for consumables later on [2][19]. Group 2: Market Dynamics and Company Performance - Companies like Wandong Medical have seen high bidding rates in 2025, with CT, MR, and DR equipment winning bids at rates of 47%, 56%, and 50% respectively, but this has come at the cost of profitability [3][20]. - Wandong Medical forecasts a net loss of 199 million to 257 million yuan for 2025, marking the worst annual performance since its listing, while Mindray's gross margin has dropped by 4.59 percentage points to 61.21% [3][15][28]. Group 3: Competitive Strategies and Industry Trends - The intense competition in the in-vitro diagnostics (IVD) sector has led to a significant reduction in the number of companies, from 2,320 to 1,530 between 2023 and 2025, with many resorting to extreme pricing strategies to capture market share [5][23]. - Companies often employ a bundling strategy, offering low-priced equipment while charging high prices for consumables, leading to increased overall costs for hospitals [6][24]. Group 4: Regulatory Responses - The national government has begun to take serious measures against low-cost bidding practices, with new regulations set to take effect in 2026 that will enforce scrutiny on bids significantly below average prices [9][25]. - Hubei Province has established specific thresholds for triggering reviews of abnormally low bids, which may be adjusted based on actual circumstances [11][27]. Group 5: Future Directions for the Medical Equipment Market - Companies are increasingly focusing on international markets and developing differentiated products to navigate the pressures of price competition [16][29]. - The need for innovation is emphasized as the industry shifts from a manufacturing to a creative approach, highlighting the importance of driving growth through new product development [30][31].

每经AI快讯，今日，和妍（上海）医疗器械有限公司收到国家药品监督管理局（NMPA）颁发的国内首 款"注射用聚左旋乳酸微球填充剂"三类医疗器械注册证。该产品经多年研发及多中心临床验证，采用预 灌封工艺实现全流程无菌管控，提升操作便捷性与安全性；核心PLLA微球生物相容、可生物降解、能 长效刺激自体胶原蛋白再生，提供自然安全的面部年轻化方案。此次获批填补行业空白，彰显企业技术 实力。 ...

爱舍伦公告，公司境外孙公司默瑞医疗科技有限公司已完成增资并在泰国政府相关部门完成注册登记证 变更手续，于2026年2月18日取得新的注册证书。默瑞医疗注册成立于2024年12月9日，注册资金为2.06 亿泰铢，经营范围包括医疗产品和医疗设备的研发、生产与销售等26项内容。 本文源自：金融界AI电报 ...

Group 1 - The core viewpoint is that Mingde Biological (002932) acknowledges that its stock price is influenced by multiple factors, including macroeconomic environment, industry conditions, and market sentiment [1] - The company states that its operations are normal and all business activities are progressing in an orderly manner [1] - There are no significant matters that should have been disclosed but were not, according to the company's response to investor inquiries [1]